Published in Hepatology on May 01, 1998
Combination Therapy for Chronic Hepatitis C Infection | NCT01805882
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut (2004) 2.22
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut (2000) 1.84
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol (2005) 1.22
Hepatitis C and liver transplantation. Gut (1999) 1.03
Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol (2007) 1.02
Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health (2013) 1.01
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut (2001) 1.00
Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol (2006) 0.97
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis (2013) 0.93
Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J Gastroenterol (2008) 0.90
Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci (2011) 0.89
Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology (2008) 0.89
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J Gastroenterol (2004) 0.88
Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut (2005) 0.86
Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol (2009) 0.84
Nutrition and exercise in the management of liver cirrhosis. World J Gastroenterol (2014) 0.83
Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open (2012) 0.83
Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol (2007) 0.82
SOCS-1 promoter methylation and treatment response in chronic hepatitis C patients receiving pegylated-interferon/ribavirin. J Clin Immunol (2013) 0.82
Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol (2016) 0.80
Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol (2014) 0.80
Effects and outcomes of interferon treatment in Japanese hepatitis C patients. BMC Gastroenterol (2012) 0.79
Visualizing the hepatic vascular architecture using superb microvascular imaging in patients with hepatitis C virus: A novel technique. World J Gastroenterol (2016) 0.79
Hepatitis C: somber views of natural history and optimistic views of interferon treatment? Hepatology (1998) 0.78
Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med (2011) 0.78
Hepatitis C virus replication and potential targets for direct-acting agents. Therap Adv Gastroenterol (2010) 0.77
Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Gastroenterol (2014) 0.77
Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. J Gastroenterol (2012) 0.77
Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. Int J Med Sci (2004) 0.76
The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection. Int J Hepatol (2011) 0.75
HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma. PLoS One (2014) 0.75
Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. World J Hepatol (2015) 0.75
Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. World J Hepatol (2015) 0.75
Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am (2017) 0.75
Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol (2017) 0.75
Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening. World J Gastroenterol (2016) 0.75
Antiviral therapy of HCV in the cirrhotic and transplant candidate. Int J Med Sci (2006) 0.75
Interferon therapy reduces the risk for hepatocellular carcinoma. Gut (2000) 0.75
Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan. PLoS One (2017) 0.75
Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines. J Gastroenterol (2012) 0.75
Albumin messenger RNA as a marker of circulating hepatocytes in hepatocellular carcinoma. Gastroenterology (1994) 2.62
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut (2005) 2.39
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol (2004) 2.39
Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med (1994) 2.31
Creatine kinase-BB: a marker of liver sinusoidal damage in ischemia-reperfusion. Hepatology (1993) 2.23
Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology (1999) 2.05
Differential HFE allele expression in hemochromatosis heterozygotes. Gastroenterology (2000) 2.04
Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol (2001) 1.98
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med (1991) 1.92
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology (1998) 1.85
Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology (1988) 1.79
Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future. J Hepatol (2000) 1.78
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.72
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology (1997) 1.63
Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol (1999) 1.58
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology (2001) 1.55
Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? J Hepatol (2001) 1.54
Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet (1987) 1.52
The cholangiographic features of severe forms of ABCB4/MDR3 deficiency-associated cholangiopathy in adults. Gastroenterol Clin Biol (2010) 1.45
Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology (1992) 1.43
Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol (2010) 1.42
Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transpl Surg (1999) 1.41
Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol (1993) 1.39
Choledocho-ureteral anastomosis in the rat. A new experimental model of long-term, total, internal bile diversion. J Hepatol (1993) 1.39
Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem (1996) 1.38
Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol (2001) 1.36
PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest (2000) 1.32
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat (2007) 1.29
Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology (1996) 1.28
Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab Invest (2001) 1.27
Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol (1994) 1.26
Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat (2011) 1.24
A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. J Clin Endocrinol Metab (2003) 1.20
Fetal microchimerism in primary biliary cirrhosis. J Hepatol (2000) 1.20
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer (2008) 1.12
Risk factors for hepatitis C virus infection in hepatitis C virus antibody ELISA-positive blood donors according to RIBA-2 status: a case-control survey. Hepatology (1993) 1.12
Pharmacological effect of somatostatin on bile secretion in man. Digestion (1989) 1.11
Chronic cholestatic diseases. J Hepatol (2000) 1.11
Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome. Oncogene (1998) 1.10
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer (2003) 1.08
The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology (2000) 1.06
Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology (1992) 1.06
Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther (1990) 1.04
Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol (2000) 1.04
Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol (1994) 1.03
Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology (1985) 1.03
Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology (1990) 1.02
Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol (1995) 1.01
Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol (1990) 1.00
Liver adenoma and focal nodular hyperplasia in a man with high endogenous sex steroids. Gastroenterology (1987) 0.99
Serum hyaluronan as a marker of liver fibrosis. J Hepatol (1995) 0.97
Gender and liver: is the liver stiffness weaker in weaker sex? Hepatology (2006) 0.96
Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology (1993) 0.96
Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology (1999) 0.95
Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol (2001) 0.95
Bile acid transport and regulating functions in the human biliary epithelium. Hepatology (2001) 0.95
[Rectal adenocarcinoma in association with lymphoma ("collision tumor")]. Gastroenterol Clin Biol (1990) 0.95
Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat (1995) 0.94
Serum bile acids and cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features. J Hepatol (1994) 0.94
Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacol Ther (1995) 0.94
Effect of lysine acetylsalicylate on biliary lipid secretion in dogs. Clin Sci Mol Med (1975) 0.93
HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation (2000) 0.93
Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology (1996) 0.92
Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology (1990) 0.92
Circulating albumin messenger RNA in hepatocellular carcinoma: results of a multicenter prospective study. Hepatology (1997) 0.90
[Celiac disease in adults. (48 cases) I. Anatomo-clinical, biological and radiological study; its course under a non-gluten diet]. Arch Fr Mal App Dig (1975) 0.90
[Tienilic acid-induced hepatitis associated with liver/kidney microsomal antibody (author's transl)]. Nouv Presse Med (1980) 0.89
Expression of blood group antigens including HLA markers in human adult liver. Tissue Antigens (1986) 0.89
Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology (1999) 0.89
Biochemical evidence that Na+,K+-ATPase is located at the lateral region of the hepatocyte surface membrane. FEBS Lett (1979) 0.89
Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology (1993) 0.88
Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients. Hepatology (1990) 0.88
Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology (1997) 0.88
Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology (2001) 0.88